Thereafter, c-KIT mutations [2, 6] followed by platelet-derived growth factor receptor alpha (PDGFRA) mutations [7] were discovered in GISTs, so small molecule targeted therapies with tyrosine kinase inhibitors [8, 9] were developed in GIST. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.